Evidence map›Paper›PMID 19027269›Full record

Trial reportSchizophrenia research2009

Results of phase 3 of the CATIE schizophrenia trial.

T Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, Sonia M Davis, Marvin S Swartz, Richard S E Keefe, Alexander L Miller, Robert A Rosenheck, John K Hsiao, CATIE Investigators

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.The international journal of neuropsychopharmacology · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Perphenazine for schizophrenia.The Cochrane database of systematic reviews · 2015
    Pooled it
  5. Pooled it
  6. Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2013
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009
    Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

T Scott StroupDepartment of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, USA. sstroup@med.unc.edu
Jeffrey A Lieberman
Joseph P McEvoy
Sonia M Davis
Marvin S Swartz
Richard S E Keefe
Alexander L Miller
Robert A Rosenheck
John K Hsiao
CATIE Investigators

Funding

PUBLIC EDUCATION CAMPAIGN ON DEPRESSION DARTN01MH090001 · NIMH · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · 1989 to 2003
$10.4M
Addressing Challenges in Schizophrenia ResearchK23MH067002 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI STROUP, THOMAS SCOTT · 2003 to 2007
$858k
NIMH NIH HHS K23 MH067002NIMH NIH HHS N01 MH090001
6 · The paper itself

Abstract

objectiveThe Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study doctor. We describe the characteristics of the patients who selected each treatment option and their outcomes.

methodTwo hundred and seventy patients entered phase 3. The open-label treatment options were monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these treatments.

resultsFew patients selected fluphenazine decanoate (n=9) or perphenazine (n=4). Similar numbers selected each of the other options (range 33-41). Of the seven common choices, those who selected clozapine and combination antipsychotic treatment were the most symptomatic, and those who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved for all groups, although the improvements were modest for the groups starting with relatively mild levels of symptoms. Side effect profiles of the medications varied considerably but medication discontinuations due to intolerability were rare (7% overall).

conclusionsPatients and their doctors made treatment selections based on clinical factors, including severity of symptoms, response to prior treatments, and physical health status. Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and clozapine was underutilized for those with poor previous response. Combination antipsychotic treatment warrants further study.

Indexed as

AdolescentAdultAgedAntipsychotic AgentsAripiprazoleBenzodiazepinesChronic DiseaseClozapineDibenzothiazepinesFemaleHospitalizationHumansMaleMiddle AgedOlanzapinePerphenazineAntipsychotic AgentsAripiprazoleBenzodiazepinesClozapineDibenzothiazepinesOlanzapinePerphenazinePiperazinesQuetiapine FumarateQuinolonesRisperidone

Identifiers

PMID19027269
PMCPMC2675163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.